• Retina/Vitreous

    Researchers treated three patients unresponsive to a short-course of Lucentis therapy with two 2-mg injections of infliximab. BCVA improved and central foveal thickness was reduced in all patients. No systemic adverse effects were observed through seven months of follow-up. While evidence is insufficient to consider infliximab an off-label treatment, the authors note that it does provide evidence of a pathogenetic link between intraocularly produced and/or acting anti-tumor necrosis factor and development of wet AMD.